Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt.
Biopharmaceutical maker Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) yesterday announced financial and operational results for the second quarter ended June 30, 2019.
The company indicated in the report that total net product sales from HETLIOZand Fanapt increased by 24% to $59.1 million in Q2/19 compared to $47.7 million in Q1/19 and were up 25% in the current quarter compared to $47.4 million in Q2/18. Net product sales for HETLIOZ increased by 31% to $37.8 million in Q2/19 versus $29.0 million in Q1/19 and were up 35% versus $28.0 million in Q2/18.
Net product sales for Fanapt were $21.2 million in the Q2/19, a 13% increase versus $18.8 million in Q1/19 and increased 10% over the $19.3 million for Q2/18. The firm reported that non-GAAP net income nearly doubled in the quarter to $15.0 million in Q2/19, or $0.28 per share, compared to a non-GAAP net income of $7.7 million, or $0.15 per share for Q2/18.
Vanda's President and CEO Mihael H. Polymeropoulos, M.D. commented, "The exceptional commercial performance of HETLIOZ and Fanapt positions Vanda to continue on its path of growth and long term value creation...The recently announced positive results from the tradipitant motion sickness study further enhance the potentially broad therapeutic utility of tradipitant as a treatment option for the millions of patients with gastroparesis, motion sickness and atopic dermatitis."
In the report the company also provided some full-year 2019 revenue guidance indicating it expects combined net product sales from both HETLIOZ and Fanapt in the range of $215 to $225 million. More specifically, it guided $137-143 million for HETLIOZ, and $78-82 million for Fanapt. The firm further raised its projected year-end cash position to greater than $275 million, up from prior guidance of $260 million.
Vanda provided key research and development highlights for Tradipitant, as well as both HETLIOZ and Fanapt. In July 2019, the company announced positive results from a Phase 2 clinical study (Motion Sifnos) of tradipitant in motion sickness, and further indicated that Vanda intends to initiate a Phase 3 program in motion sickness in 2019 with a plan to file for marketing authorization in 2020.
Vanda Pharmaceuticals describes itself as a biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon) for treatment of non-24-hour sleep-wake disorder (Non-24) and Fanapt (iloperidone) used for the treatment of schizophrenia. The firm's pipeline includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is in clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase (HDAC) inhibitor; and AQW051, which is a Phase 2 alpha-7 nicotinic acetylcholine receptor partial agonist with indications for the treatment of central nervous system disorders.
Vanda's shares opened nearly 20% higher today at $15.50 (+$3.05, +19.68%) over the prior day's closing price of $12.45. In early trading shares traded up higher than 36% in the range of $14.72 to $17.00, and closed at $15.79 (+3.34, +26.83%).
Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.
 Newsletter Sign-Up |
|
|
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer . This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.